Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study

Blood (2025) 146 (Supplement 1): 4232.

https://doi.org/10.1182/blood-2025-4232

Published: 2025

Journal Articles

The MEASURE Genome Atlas: Acute Myeloid Leukemia at diagnosis and complete remission

Kai Yu, Laura Dillon, Jesse Tettero, Gege Gui, Rasha Al-Ali, Michael Grunwald, Elizabeth Krakow, Elizabeth Griffiths, Alexandra Gomez-Arteaga, Rahul Vedula, Melhem Solh, Amandeep Salhotra, Nelli Bejanyan, Lori Muffly, Antonio Jimenez-Jimenez, Michael Drazer, Yi-Bin Chen, Aaron Logan, Reena Jayani-Kosarzycki, Sophia Balderman, James Blachly, Brian Shaffer, Marc Schwartz, Cecilia Yeung, Lawrence Druhan, Vanessa Kennedy, Sandeep Gurbuxani, Melissa Tjota, Max Smith, Farah Sahoo, Dylan Barfield, Jim Guo, James Han, Jason Hu, Heejoon Jo, Vidya Kudlingar, Wilfred Li, Yutong Qiu, Pratheesh Sathyan, Sean Truong, Severine Catreux, Sam Ng, Khai Luong, Yunjiao Zhu, Reem Bahr, Jamie Diemer, Jianqun Kou, Stephanie Bo-Subait, Jackie Bjerke, Steven Devine, Bergetta Dietel, Christina Ferrone, Gabrielle Giammarino, Emily Heying, Emily Kolb, Danielle O'Donnell Vitali, Wael Saber, Stephen Spellman, Brenna Tesch, Jenny Vogel, Stephanie Waldvogel, Syreeta Weatherspoon, Jeffery Auletta, Christopher Hourigan

Blood (2025) 146 (Supplement 1): 455.

https://doi.org/10.1182/blood-2025-455

Published: 2025

Journal Articles

Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial

Blood (2025) 146 (Supplement 1): 2477.

https://doi.org/10.1182/blood-2025-2477

Published: 2025

Journal Articles

Observational comparison of orca-T to registry-based post-transplant cyclophosphamide patients using matched unrelated donors

Blood (2025) 146 (Supplement 1): 6029.

https://doi.org/10.1182/blood-2025-6029

Published: 2025

Journal Articles

Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP sponsored ACCESS study

Blood (2025) 146 (Supplement 1): 936.

https://doi.org/10.1182/blood-2025-936

Published: 2025

Journal Articles

Mosunetuzumab and polatuzumab combined with axicabtagene ciloleucel induce high complete response rates at day+90 in Relapsed/Refractory large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 1009.

https://doi.org/10.1182/blood-2025-1009

Published: 2025

Journal Articles

Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial

Lucía Pérez-Lamas, Juan Carlos Hernandez Boluda, Luis Felipe Casado Montero, Maria Teresa Gómez Casares, Rosa Ayala, Blanca Xicoy, Francisca Ferrer Marin, Guillermo Orti, Raquel De Paz Arias, Santiago Osorio Prendes, Raul Perez Lopez, Elvira Mora, Concepción Ruiz Nuño, Antonio Jimenez Velasco, Concepcion Boque, Magdalena Sierra Pacho, Joaquin Martinez Lopez, Valentin Garcia Gutierrez

Blood (2023) 142 (Supplement 1): 1795.

https://doi.org/10.1182/blood-2023-184989

Published: 2023

Journal Articles

Access: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies

Monzr M. Al Malki, Steven M Devine, Bronwen E. Shaw, Larisa Broglie, Muna Qayed, Sung W. Choi, Stephen R. Spellman, Craig Malmberg, Eric Ndifon, Brent Logan, Jeffery Auletta, Heather E Stefanski, Janelle A. Olson, Antonio Jimenez Jimenez

Blood (2022) 140 (Supplement 1): 7591–7593.

https://doi.org/10.1182/blood-2022-162581

Published: 2022

Journal Articles

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Lucía Pérez-Lamas, Alejandro Luna, Concepcion Boque, María Alicia Senin, Blanca Xicoy, Pilar Giraldo, Raul Perez Lopez, Concepción Ruiz Nuño, Natalia De las Heras, Elvira Mora Casterá, Carmen Garcia-Hernandez, Adrian Segura Diaz, Juan Luis Steegmann, Patricia Velez Tenza, Fermin Sanchez-Guijo, Ana Maria Garcia-Noblejas Moya, Juan Antonio Juan Vera Goñi, Melania Moreno Vega, Alberto Alvarez-Larran, Montse Cortes, Manuel Perez Encinas, Luis Serrano, Anna Angona, Ana Rosell, Sunil Lakhwani, Mercedes Colorado, Elena Ramila, Carlos Cervero, Beatriz Cuevas, Lucia Villalon Blanco, Juan Carlos Hernandez Boluda, Antonio Paz Coll, Valle Gómez García de Soria, Maria Jose Fernández, Luis Felipe Casado, Juan Manuel Alonso-Dominguez, Maria Magdalena Anguita Arance, Patricia Carrascosa Mastell, Araceli Salamanca Cuenca, Antonio Jiménez-Velasco, María José Ramírez, Miguel López Esteban, Magdalena Sierra Pacho, Marta Santaliestra, Olga Alda Alvarez, Raquel de Paz, Valentín García Gutiérrez

Blood (2022) 140 (Supplement 1): 3925–3928.

https://doi.org/10.1182/blood-2022-167453

Published: 2022

Journal Articles

Asciminib in Real-Life Clinical Practice, Safety and Efficacy Profile in Chronic Myeloid Leukemia Pretreated Patients

Lucía Pérez-Lamas, Alejandro Luna, Concepcion Boque, Pilar Giraldo, Blanca Xicoy, Luis Felipe Casado, Fermin Sanchez-Guijo, Concepción Ruiz Nuño, Melania Moreno Vega, Alberto Alvarez-Larran, Araceli Salamanca Cuenca, Ana García-Noblejas, Ferran Vall-Llovera, Manuel Perez Encinas, Lucia Villalon, Natalia De las Heras, Sunil Lakhwani, Elena Ramila, Beatriz Cuevas, Raul Perez Lopez, Antonio Jiménez-Velasco, Ana Rosell, Angeles Escola, Maria Jose Fernández, Carmen Garcia-Hernandez, Carlos Cervero, Elvira Mora Casterá, Miguel Sagüés, Sara Suarez-Varela, Patricia Vélez, Patricia Carrascosa Mastell, Rocio Fé Bitaube, Luis Serrano, Montse Cortes, Juan Antonio Juan Vera Goñi, Juan Luis Steegmann, Juan Carlos Hernandez Boluda, Valle Gomez, Juan Manuel Alonso-Dominguez, Mercedes Colorado Araujo, Antonio Paz Coll, Valentín Garcia Gutierrez

Blood (2021) 138 (Supplement 1): 2563.

https://doi.org/10.1182/blood-2021-150813

Published: 2021

Journal Articles

Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-137677

Published: 2020

Journal Articles

Impact of Comorbidities on Response Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with First-Line Dasatinib Versus Imatinib: Exploratory Post Hoc Analysis of DASISION

Massimo Breccia, MD, Michael J. Mauro, MD, Elias Jabbour, MD, Giuseppe Saglio, MD PhD, Antonio Jiménez-Velasco, MD, Philipp D le Coutre, MD, Irene DeGutis, PharmD, Wasiulla Khan, PhD, Oumar Sy, PhD, Rene Swanink, Jorge E. Cortes, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-137636

Published: 2020

Journal Articles

Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-138690

Published: 2020

Journal Articles

Association of High Body Mass Index with Response Outcomes in Patients with CML-CP Treated with Dasatinib Versus Imatinib in the First Line: Exploratory Post Hoc Analysis of the Phase 3 DASISION Trial

Massimo Breccia, MD, Jorge E. Cortes, MD, Neil P Shah, MD PhD, Giuseppe Saglio, MD, Antonio Jiménez-Velasco, MD, Philipp Le Coutre, MD, Alexander Brun, PharmD, Irene DeGutis, Sai Bathena, Oumar Sy, PhD, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 4155.

https://doi.org/10.1182/blood-2019-121872

Published: 2019

Journal Articles

Updated 18-Month Results from Dasfree: A Study Evaluating Dasatinib Discontinuation in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)

Neil P. Shah, MD PhD, Jose Valentín García Gutiérrez, MD PhD, Antonio Jiménez-Velasco, MD, Sarah Larson, MD, Susanne Saussele, MD, Delphine Rea, MD, François-Xavier Mahon, MD PhD, Moshe Yair Levy, MD, María Teresa Gómez-Casares, MD PhD, Fabrizio Pane, MD, Franck-Emmanuel Nicolini, MD PhD, Michael J. Mauro, MD, Oumar Sy, PhD, Patricia Martin Regueira, MD, Jeffrey H. Lipton, MD PhD

Blood (2018) 132 (Supplement 1): 4253.

https://doi.org/10.1182/blood-2018-99-116563

Published: 2018

Journal Articles

Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)

Neil P. Shah, MD PhD, Jose Valentín García Gutiérrez, PhD, Antonio Jiménez-Velasco, MD, Sarah M Larson, MD, Susanne Saussele, MD, Delphine Rea, MD, François-Xavier Mahon, MD PhD, Moshe Levy, MD, María Teresa Gómez-Casares, MD PhD, Fabrizio Pane, MD, Franck-Emmanuel Nicolini, MD PhD, Michael J. Mauro, MD, Oumar Sy, PhD, Patricia Martin-Regueira, MD, Jeffrey H. Lipton, PhD MD FRCPC

Blood (2017) 130 (Supplement 1): 314.

https://doi.org/10.1182/blood.V130.Suppl_1.314.314

Published: 2017

Journal Articles

A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy

Blood (2017) 130 (Supplement 1): 1624.

https://doi.org/10.1182/blood.V130.Suppl_1.1624.1624

Published: 2017

Journal Articles

Treatment-Free Remission (TFR) in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) and in Stable Deep Molecular Response (DMR) to Dasatinib - the Dasfree Study

Neil P. Shah, MD PhD, Ronald Paquette, MD, Martin C. Müller, MD, Susanne Saussele, MD, Valentin Garcìa-Gutiérrez, MD, Antonio Jiménez-Velasco, MD, Franck-Emmanuel Nicolini, MD PhD, Michael J. Mauro, MD, Francois-Xavier Mahon, MD PhD, Delphine Rea, MD PhD, Patricia Martin-Regueira, MD, Milayna Subar, MD, Li Li, PhD, Jeffrey H. Lipton, MD PhD

Blood (2016) 128 (22): 1895.

https://doi.org/10.1182/blood.V128.22.1895.1895

Published: 2016

Journal Articles

The Molecular Response at 3 Months, Measured Using a Genxpert Platform, Predicts Further Outcomes in Chronic Myeloid Patients, but the Cutoff Differs from the 10% Cutoff Commonly Used with the EUTOS Method

Valentín García Gutiérrez, María Teresa Gómez-Casares, Jose Manuel Puerta, Juan Manuel Alonso, Santiago Osorio, Juan Carlos Hernández-Boluda, Rosa Collado, Maria Jose Ramirez, MD, Fatima Ibañez, MD, Maria Luisa Martin, Juan Diego Rodriguez, Carolina Martinez-Laperche, Montse Gomez, Viviana Fiallo, Redondo Sara, Alicia Rodriguez, Concepcion Ruiz, Juan Luis Steegmann, MD, Antonio Jiménez-Velasco, MD

Blood (2016) 128 (22): 1906.

https://doi.org/10.1182/blood.V128.22.1906.1906

Published: 2016

Journal Articles

Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients

Valentín García-Gutiérrez, Dragana Milojkovic, María Luisa Martín Mateos, Simone Claudiani, Concepcion Boque, PhD, Luis Felipe Casado, Gloria González, Antonio Jiménez, Alejandra Martinez Trillos, Isabel Mata Vázquez, Ángel Ramírez Payer, Alberto Álvarez Larran, Elena Amutio Díez, Abelardo Bárez García, MD, Guiomar Bautista Carrascosa, Sabela Bobillo Varela, Beatriz Cuevas Ruiz, Mª Ángeles Fernández Fernández, María del Carmen García Garay, Pilar Giraldo, MD PhD, Jose María Guinea de Castro, Natalia De Las Heras Rodríguez, MD, Nuria Hernanz Soler, Ana Iglesias Pérez, José Luis López Lorenzo, Josep Maria Martí Tutusaus, MD PhD, Rolando Omar Vallansot, Fernando Ortega Rivas, Jose Manuel Puerta, Maria Jose Ramírez Sánchez, Esperanza Romero Picos, Mario Andrés Romo Collada, Ana Rosell Mas, Silvana Saavedra Gerosa, Ana Sebrango Sadia, José Tallón Pérez, Sandra Valencia, Juan Luis Steegmann, MD

Blood (2015) 126 (23): 2786.

https://doi.org/10.1182/blood.V126.23.2786.2786

Published: 2015

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study

The MEASURE Genome Atlas: Acute Myeloid Leukemia at diagnosis and complete remission

Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial

Observational comparison of orca-T to registry-based post-transplant cyclophosphamide patients using matched unrelated donors

Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP sponsored ACCESS study

Mosunetuzumab and polatuzumab combined with axicabtagene ciloleucel induce high complete response rates at day+90 in Relapsed/Refractory large B-cell lymphoma

Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial

Access: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Asciminib in Real-Life Clinical Practice, Safety and Efficacy Profile in Chronic Myeloid Leukemia Pretreated Patients

Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative

Impact of Comorbidities on Response Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with First-Line Dasatinib Versus Imatinib: Exploratory Post Hoc Analysis of DASISION

Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure

Association of High Body Mass Index with Response Outcomes in Patients with CML-CP Treated with Dasatinib Versus Imatinib in the First Line: Exploratory Post Hoc Analysis of the Phase 3 DASISION Trial

Updated 18-Month Results from Dasfree: A Study Evaluating Dasatinib Discontinuation in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)

Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)

A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy

Treatment-Free Remission (TFR) in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) and in Stable Deep Molecular Response (DMR) to Dasatinib - the Dasfree Study

The Molecular Response at 3 Months, Measured Using a Genxpert Platform, Predicts Further Outcomes in Chronic Myeloid Patients, but the Cutoff Differs from the 10% Cutoff Commonly Used with the EUTOS Method

Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only